SUNRISE-PD evaluating the Company’s anti-inflammatory, insulin-sensitizing candidate bezisterim in patients with Parkinson’s disease who have not ...

For patients with Parkinson disease with motor fluctuations, the oral once-daily, selective D1/D5 partial dopamine agonist tavapadon as an adjunct to levodopa increases total daily ON time vs placebo.

Therapies that use stem cells to repair or replace damaged cells in the brains of patients with Parkinson’s disease have been ...

The highly selective partial agonist at D1 and D5 receptors significantly improves motor function in patients recently ...

AbbVie has launched its Produodopa therapy for Parkinson’s disease onto the market in the EU, becoming the first and only 24-hour levodopa-based subcutaneous infusion therapy for the ...

Propranolol Reduces Tremors in Parkinson's Disease Dec. 23, 2024 — The standard medication levodopa does not always work against tremors in Parkinson's disease, especially in stressful situations.

New research to be presented at the European Congress on Obesity (ECO 2025, Malaga, Spain, 11–14 May) shows that around two-thirds of participants of the SURMOUNT-1 trial had only regained 5% or ...

A longstanding mystery in Parkinson's disease research has been why some individuals carrying pathogenic variants that increase their risk of PD go on to develop the disease, while others who also ...